A Dual Killing Strategy: The University of EdinburghFinally, to explore the scope of this Pt(IV) prodrug activation system, the ability of two ruthenium-based photosensitisers to reduce three different Pt(IV) species was shown (Figure S17). TLD-1433, a photosensitiser currently under clinical investigation, was capable of reducing two oxaliplatin Pt(IV) species upon illumination of light. This was also shown to be possible with other platinum drugs, such as a Pt(IV) cisplatin derivative (Cpt-Ac).
In conclusion, a photocatalytic platform for the simultaneous activation of Pt(IV) prodrugs and generation of singlet oxygen has been developed utilising a ruthenium-based photosensitiser. This system demonstrated excellent cytotoxic capabilities following illumination of cancer cell lines. The prodrug activation system overcame acquired Pt resistance in cells and demonstrated robustness in each of the cell lines used ((Title)) (ed.ac.uk)